• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Nuvectis Pharma Inc.

    4/29/24 4:33:03 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVCT alert in real time by email
    DEFA14A 1 tm243018d2_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. _____)

      

    Filed by the Registrant x
       
    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨  Preliminary Proxy Statement
    ¨  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨  Definitive Proxy Statement
    x  Definitive Additional Materials
    ¨  Soliciting Material under Rule14a-12

     

    NUVECTIS PHARMA, INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    x  No fee required.
    ¨  Fee paid previously with preliminary materials.
    ¨  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

    GRAPHIC

    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V29561-P04828 NUVECTIS PHARMA, INC. 1 BRIDGE PLAZA, SUITE 275 FORT LEE, NJ 07024 ATTN: MICHAEL CARSON NUVECTIS PHARMA, INC. 2024 Annual Meeting Vote by June 12, 2024 11:59 PM ET You invested in NUVECTIS PHARMA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 13, 2024. Vote Virtually at the Meeting* June 13, 2024 10:00 AM, EDT Virtually at: www.virtualshareholdermeeting.com/NVCT2024 *Please check the meeting materials for any special requirements for meeting attendance. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 30, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V29562-P04828 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of Directors Nominees: 1a. Kenneth Hoberman For 1b. Matthew Kaplan For 2. Ratify the appointment of Kesselman & Kesselman as our independent registered public accounting firm for the year ending December 31, 2024. For NOTE: Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.

    Get the next $NVCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVCT

    DatePrice TargetRatingAnalyst
    4/2/2025$17.00Buy
    Maxim Group
    3/17/2025$19.00Buy
    Laidlaw
    7/13/2022$21.00Buy
    Ladenburg Thalmann
    3/2/2022$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NVCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Bentsur Ron bought $28,600 worth of shares (5,000 units at $5.72), increasing direct ownership by 0.14% to 3,525,924 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:01:11 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sanchez Juan bought $75,270 worth of shares (13,000 units at $5.79), increasing direct ownership by 20% to 78,150 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:00:38 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaplan Matthew L. bought $64,240 worth of shares (11,000 units at $5.84), increasing direct ownership by 10% to 124,760 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:00:15 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Nuvectis Pharma with a new price target

    Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00

    4/2/25 8:05:05 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw initiated coverage on Nuvectis Pharma with a new price target

    Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00

    3/17/25 7:40:44 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

    Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00

    7/13/22 8:35:52 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    SEC Filings

    View All

    Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

    11/4/25 8:16:48 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Nuvectis Pharma Inc.

    10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

    11/4/25 8:01:41 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

    9/25/25 8:23:11 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Dev. & Ops. Officer Shemesh Shay was granted 150,000 shares, increasing direct ownership by 9% to 1,793,068 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    1/9/26 4:32:18 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman & CEO Bentsur Ron was granted 150,000 shares, increasing direct ownership by 4% to 3,675,924 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    1/9/26 4:31:39 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Science & Business Off Poradosu Enrique was granted 150,000 shares, increasing direct ownership by 9% to 1,806,319 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    1/9/26 4:30:55 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

    Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osimertinib is Tagrisso®, marketed by Astra Zeneca. Tagrisso, a 3rd generation EGFR inhibitor is broadly used in patients with NSCLCmut+ as single agent or in combination with chemotherapy a

    12/17/25 7:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

    Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT, the "Company")), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, including the combination with osimertinib in non-small cell lung cancer. To register for the event, click here. The event will feature Alexander Spira, MD, PhD, FACP, FASCO (Chief Scientific Officer, NEXT Oncology) and Asier Unc

    11/25/25 8:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

    FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ:NVCT), the tables were not included. The tables have been added and the corrected release follows: NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-endNXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dos

    11/4/25 8:15:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Financials

    Live finance-specific insights

    View All

    Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

    The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of

    8/11/25 4:30:00 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

    Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025 for $14.6 billion. Ron Bentsur, Chairman and Chief Executive Officer of Nuvec

    9/25/25 8:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

    SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

    11/5/24 10:55:09 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

    SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

    2/28/24 8:37:52 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nuvectis Pharma Inc.

    SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)

    2/6/24 8:47:33 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care